< LEADERBOARD/s/beta-glucanFiber & immune

Beta-Glucan

Also sold as: Oat beta-glucan · Barley beta-glucan · Yeast beta-glucan · Fungal beta-glucan

A family of polysaccharides from cereals, yeast and fungi. Cereal fiber and immune-oriented extracts have distinct structures and evidence.

Longevity

COMMUNITY_STACK_RATINGlive · n=0

Community

Not enough ratings yet: 0 of 10

Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.

+ Rate your experience (30 sec, anonymous)

NERD_PROTOCOL // EVIDENCE_MATRIXper goal

Research

LongevityNo established evidence

Longevity: LDL and post-meal glucose changes do not establish longer life or fewer cardiovascular events.

REALITY CHECK // Cereal beta-glucan (1,3/1,4) is viscous fiber with strong LDL and post-meal glucose evidence. A 28-RCT meta-analysis found LDL lower by 0.25 mmol/L (reported CI magnitude 0.20-0.30) and total cholesterol lower by 0.30 mmol/L, without clear HDL or triglyceride changes. Yeast/fungal beta-glucans (1,3/1,6) have separate, less certain respiratory-symptom evidence from small heterogeneous studies.

Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.

Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.

CHECK_YOUR_BOTTLE.EXEruns in your browser · nothing is sent or stored

Check your bottle

Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.

Enter the amount from your label to see the result.

How it was studied

01 // STUDIED_DOSE_RANGE

Study exposure, not a prescription

Cereal trials used about 3.0-12.4 g/day of actual beta-glucan over 2-12 weeks; 3 g/day is the commonly cited cholesterol amount. Yeast trials commonly used 100-500 mg/day for 4-12 weeks. Different materials cannot be exchanged by matching capsule weight.

02 // TIMING_&_MATRIX

Cereal fiber acts within the meal

Cereal fiber acts locally through intestinal viscosity and altered bile-acid and glucose handling; molecular weight and processing matter. Yeast/fungal structures engage innate immune receptors such as Dectin-1. Receptor activation does not demonstrate infection prevention or cancer therapy.

03 // EVALUATION_WINDOW

2-12 weeks; meal effects can be acute

Acute biochemical responses and chronic clinical outcomes have different evaluation windows; the outcome notes specify the study context.

04 // SAFETY_&_QUALITY_GATE

Material, medicines and tolerability

Immunosuppression, transplantation or autoimmune disease requires clinician review before yeast/fungal extracts; this is a theoretical concern, not proven harm. Supplemental immune-extract safety during pregnancy/breastfeeding is insufficient. Added cereal fiber can aggravate IBS/IBD symptoms.

UPPER LIMIT // No established EFSA/NIH UL is supplied for isolated beta-glucan. Gastrointestinal tolerance limits cereal fiber; long-term high-dose immune-extract toxicology is uncertain. Official health-claim wording was not checked live.

NERD'S NOTENerd Protocols · a clinical and sports dietitian based in the EU

Summary

Cereal beta-glucan (1,3/1,4) is viscous fiber with strong LDL and post-meal glucose evidence. A 28-RCT meta-analysis found LDL lower by 0.25 mmol/L (reported CI magnitude 0.20-0.30) and total cholesterol lower by 0.30 mmol/L, without clear HDL or triglyceride changes. Yeast/fungal beta-glucans (1,3/1,6) have separate, less certain respiratory-symptom evidence from small heterogeneous studies.

Mechanism

Typical studied dose

Upper limit

No established EFSA/NIH UL is supplied for isolated beta-glucan. Gastrointestinal tolerance limits cereal fiber; long-term high-dose immune-extract toxicology is uncertain. Official health-claim wording was not checked live.

POPULAR_STACKScombos with n ≥ 5

Popular stacks with Beta-Glucan

Not enough stack data yet. A combination with Beta-Glucan appears here once 5 people rate the same set.

> Rate my stack

Forms and label traps

Forms compared
Form on label	Active content	Studied range / day	Absorption & GI tolerance	Verdict
Oat or barley beta-glucan (1,3/1,4) Best for: LDL and post-meal glucose endpoints.	Unstandardized: active content unknown	no comparable trial range	Local viscosity rather than systemic absorption. Gas and bloating when intake rises quickly.	Caution [CHECK // MATERIAL_AND_LABEL] Actual beta-glucan concentration is unspecified. No confident conversion of flour/extract mass to trial-active fiber is possible. PMID 25411276 PMID 33608654
Yeast beta-glucan (1,3/1,6) Best for: Limited respiratory-symptom evidence.	Extract weight · marker not quantified	100–500 mg	Immune recognition in gut-associated tissues. Generally tolerated at trial quantities; individual response varies.	Good option [CHECK // MATERIAL_AND_LABEL] Compare trial-material mass at 100-500 mg/day only with matching preparations. The source supplies no product-specific marker assay; zero indicates unknown concentration, not absence of beta-glucan. PMID 28606567 PMID 23378458
Fungal beta-glucan (pleuran/lentinan preparations) Best for: Preparation-specific respiratory research.	Unstandardized: active content unknown	no comparable trial range	Innate immune recognition; oral supplements differ from injected medicines. Preparation-dependent; long-term evidence limited.	Caution [CHECK // MATERIAL_AND_LABEL] Source, fruiting body/mycelium and assay matter. No transferable numeric range is established for an arbitrary mushroom extract. PMID 21249381 PMID 36324817

Common label traps

TRAP_01 // All beta-glucans lower cholesterol
The strongest lipid evidence concerns oat/barley 1,3/1,4 fiber, not interchangeable immune extracts.
TRAP_02 // An immune booster treats cancer
Preclinical reviews and injectable lentinan evidence do not establish cancer benefit from an oral supplement.
TRAP_03 // More extract always means more effect
Cereal efficacy depends on actual beta-glucan and preserved viscosity; an unassayed extract number establishes neither.

Other outcomes studied

Outside the five leaderboard goals. Same evidence levels as above.

LDL CHOLESTEROL Strong · benefit
Cereal fiber reduces LDL by about 0.25 mmol/L in the cited 28-RCT synthesis; this is a biomarker endpoint.
PMID 25411276 PMID 27724985 PMID 35631184 PMID 34977959 PMID 38441173 PMID 41362998
POST-MEAL GLUCOSE Strong · benefit
Oat beta-glucan reduces meal-related glucose and insulin responses; dose and preserved viscosity matter.
PMID 33608654 PMID 26690472 PMID 42559073
RESPIRATORY SYMPTOMS Limited · benefit
Small heterogeneous yeast/fungal studies suggest fewer symptomatic days; some evidence is open-label.
PMID 18614945 PMID 28606567 PMID 23378458 PMID 23927572 PMID 21249381 PMID 24149590 PMID 36324817 PMID 40746014 PMID 33876798 PMID 40021713
ORAL CANCER THERAPY No established evidence
No clinical oral-supplement cancer benefit is established; mechanistic work and injectable drugs are different evidence.
PMID 36046144 PMID 39091181

Reader questions

Should I choose oat or yeast material?

Oat/barley fiber matches lipid and meal-response research; yeast/fungal extracts have separate, weaker immune evidence.

Does extract weight equal beta-glucan content?

No. Actual beta-glucan content requires a product-specific assay.

Can I use immune extracts after transplantation?

Discuss this with the transplant team. The concern is theoretical immune opposition and cannot be resolved from cereal-fiber trials.

Stack interactions

Caution Glucose-lowering medicines [CAUTION // CONTEXT_MATTERS]
Meal-related glucose lowering makes additivity possible; a clinically significant interaction is not demonstrated.
PMID 33608654
Caution Immunosuppressants [CAUTION // CONTEXT_MATTERS]
Theoretical opposition to immune suppression warrants review in transplant/autoimmune care; clinical harm is not proven.
Caution Psyllium or other viscous fibers [CAUTION // CONTEXT_MATTERS]
Combined products can increase bloating; superiority of a mixed stack is not established.

Red flags: interactions and who should avoid it

Interactions

Cereal fiber may add to glucose-lowering medicines and affect simultaneous oral-drug absorption; the latter magnitude is unverified. Yeast/fungal immune activity creates theoretical caution with immunosuppressants. Other fibers may add bloating.

Avoid or ask a doctor first if

Sources (PubMed, 21)

Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials.
PMID 25411276 · 2014 · Journal Article; Meta-Analysis; Research Support; Non-U.S. Gov't
Cereal fiber reduces LDL by about 0.25 mmol/L in the cited 28-RCT synthesis; this is a biomarker endpoint.
The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials.
PMID 27724985 · 2016 · Journal Article; Meta-Analysis; Systematic Review
Cereal fiber reduces LDL by about 0.25 mmol/L in the cited 28-RCT synthesis; this is a biomarker endpoint.
Effects of Oat Beta-Glucan Intake on Lipid Profiles in Hypercholesterolemic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PMID 35631184 · 2022 · Journal Article; Meta-Analysis; Systematic Review
Cereal fiber reduces LDL by about 0.25 mmol/L in the cited 28-RCT synthesis; this is a biomarker endpoint.
Effect of oat supplementation interventions on cardiovascular disease risk markers: a systematic review and meta-analysis of randomized controlled trials.
PMID 34977959 · 2022 · Journal Article; Meta-Analysis; Systematic Review
Cereal fiber reduces LDL by about 0.25 mmol/L in the cited 28-RCT synthesis; this is a biomarker endpoint.
Efficacy of oats in dyslipidemia: a systematic review and meta-analysis.
PMID 38441173 · 2024 · Journal Article; Meta-Analysis; Systematic Review
Cereal fiber reduces LDL by about 0.25 mmol/L in the cited 28-RCT synthesis; this is a biomarker endpoint.
Cereal beta-glucan and cardiovascular disease risk reduction in overweight and obese populations: a systematic review and meta-analysis of lipid, blood pressure, and anthropometric parameters.
PMID 41362998 · 2026 · Journal Article; Meta-Analysis; Systematic Review
Cereal fiber reduces LDL by about 0.25 mmol/L in the cited 28-RCT synthesis; this is a biomarker endpoint.
The effect of oat β-glucan on postprandial blood glucose and insulin responses: a systematic review and meta-analysis.
PMID 33608654 · 2021 · Journal Article; Meta-Analysis; Research Support; Non-U.S. Gov't; Systematic Review
Oat beta-glucan reduces meal-related glucose and insulin responses; dose and preserved viscosity matter.
The Metabolic Effects of Oats Intake in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
PMID 26690472 · 2015 · Journal Article; Meta-Analysis; Research Support; Non-U.S. Gov't; Systematic Review
Oat beta-glucan reduces meal-related glucose and insulin responses; dose and preserved viscosity matter.
Clinical and mechanistic evidence on metabolic effects of oat β-glucan, rice bran, and unripe banana flour: a systematic review with mechanism-informed synthesis.
PMID 42559073 · 2026 · Journal Article; Systematic Review
Oat beta-glucan reduces meal-related glucose and insulin responses; dose and preserved viscosity matter.
Beta-glucan, immune function, and upper respiratory tract infections in athletes.
PMID 18614945 · 2008 · Journal Article; Randomized Controlled Trial; Research Support; Non-U.S. Gov't
Small heterogeneous yeast/fungal studies suggest fewer symptomatic days; some evidence is open-label.
Yeast-derived β-1,3/1,6 glucan, upper respiratory tract infection and innate immunity in older adults.
PMID 28606567 · 2017 · Journal Article; Randomized Controlled Trial
Small heterogeneous yeast/fungal studies suggest fewer symptomatic days; some evidence is open-label.
Baker's yeast beta-glucan supplement reduces upper respiratory symptoms and improves mood state in stressed women.
PMID 23378458 · 2012 · Journal Article; Randomized Controlled Trial; Research Support; Non-U.S. Gov't
Small heterogeneous yeast/fungal studies suggest fewer symptomatic days; some evidence is open-label.
Baker's yeast beta glucan supplementation increases salivary IgA and decreases cold/flu symptomatic days after intense exercise.
PMID 23927572 · 2013 · Journal Article; Randomized Controlled Trial; Research Support; Non-U.S. Gov't
Small heterogeneous yeast/fungal studies suggest fewer symptomatic days; some evidence is open-label.
Pleuran (β-glucan from Pleurotus ostreatus) supplementation, cellular immune response and respiratory tract infections in athletes.
PMID 21249381 · 2011 · Journal Article; Randomized Controlled Trial; Research Support; Non-U.S. Gov't
Small heterogeneous yeast/fungal studies suggest fewer symptomatic days; some evidence is open-label.
Effect of BETA 1, 3/1, 6 GLUCAN on Upper Respiratory Tract Infection Symptoms and Mood State in Marathon Athletes.
PMID 24149590 · 2009 · Journal Article
Small heterogeneous yeast/fungal studies suggest fewer symptomatic days; some evidence is open-label.
Beta-(1,3/1,6)-D-glucan from Pleurotus ostreatus in the prevention of recurrent respiratory tract infections: An international, multicentre, open-label, prospective study.
PMID 36324817 · 2022 · Journal Article
Small heterogeneous yeast/fungal studies suggest fewer symptomatic days; some evidence is open-label.
Yeast Beta-Glucan Enhances Antibody Response Following Influenza Vaccination - A Double-Blind, Randomized, Placebo-Controlled Pilot Trial.
PMID 40746014 · 2025 · Journal Article; Randomized Controlled Trial
Small heterogeneous yeast/fungal studies suggest fewer symptomatic days; some evidence is open-label.
Effects of fungal beta-glucans on health - a systematic review of randomized controlled trials.
PMID 33876798 · 2021 · Journal Article; Systematic Review
Small heterogeneous yeast/fungal studies suggest fewer symptomatic days; some evidence is open-label.
Beneficial effects of pleuran on asthma control and respiratory tract-infection frequency in children with perennial asthma.
PMID 40021713 · 2025 · Journal Article; Randomized Controlled Trial; Multicenter Study
Small heterogeneous yeast/fungal studies suggest fewer symptomatic days; some evidence is open-label.
Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review.
PMID 36046144 · 2021 · Journal Article; Review; not classified as human evidence in source catalog
No clinical oral-supplement cancer benefit is established; mechanistic work and injectable drugs are different evidence.
Investigating the Immune-Stimulating Potential of β-Glucan from Aureobasidium pullulans in Cancer Immunotherapy.
PMID 39091181 · 2024 · Journal Article; not classified as human evidence in source catalog
No clinical oral-supplement cancer benefit is established; mechanistic work and injectable drugs are different evidence.

Community comments

No approved comments yet. Comments are held for moderation.

+ Rate this